Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Notes Payables (2020)

Protara Therapeutics' Notes Payables history spans 2 years, with the latest figure at $370793.0 for Q3 2020.

  • Quarterly Notes Payables changed N/A to $370793.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $370793.0 through Sep 2020, changed N/A year-over-year, with the annual reading at $3.7 million for FY2013, N/A changed from the prior year.
  • Notes Payables came in at $370793.0 for Q3 2020, down from $926983.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.3 million in Q1 2020 to a low of $370793.0 in Q3 2020.